Low-Field High-Performance MRI for Screening Clinically Significant Prostate Cancer
低场高性能 MRI 用于筛查有临床意义的前列腺癌
基本信息
- 批准号:10306404
- 负责人:
- 金额:$ 19.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAddressAdvisory CommitteesAmerican Cancer SocietyAmplifiersAreaBiopsyBlood TestsCancer EtiologyClinicalDepositionDetectionDiagnosisDiagnosticDiagnostic ImagingDiffusionDiffusion Magnetic Resonance ImagingDiseaseEarly DiagnosisEarly treatmentEvaluationFellowshipFundingGasesHeliumHip region structureHumanImageImage EnhancementIncidenceIntestinesLiteratureMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMethodologyMethodsNoiseOwnershipPSA screeningPathway interactionsPatientsPerformancePlayPopulationPredispositionPreventiveProstateProstate-Specific AntigenProtocols documentationReportingResearchResolutionRoleSafetySamplingScanningScreening for Prostate CancerScreening procedureSensitivity and SpecificitySignal TransductionSourceSpecificitySystemT2 weighted imagingTechniquesTestingTimeTrainingUnited StatesUnited States National Institutes of HealthUrsidae Familyagedbasecancer careclinical implementationclinically significantcontrast enhancedcostcost estimatedeep learningdenoisingdesigneconomic impacthead-to-head comparisonhealthy volunteerimage reconstructionimaging scientistimaging systemimprovedinnovationlight weightmalemenmortalitynoveloperationprostate lesionsprototyperadiologistreconstructionscreeningscreening guidelinestheoriestumorvolunteer
项目摘要
Project Summary/Abstract
Prostate cancer (PCa) is the most common malignancy and is the 2nd leading cause of cancer-related mortality
in males in the United States. Despite high incidence and tremendous human and economic impact of PCa,
there is no good screening test for clinically significant PCa. Commonly used blood test for Prostate Specific
Antigen (PSA) is inexpensive but lack specificity for clinically significant PCa. Over the last decade, multi-
parametric prostate MRI has been shown to have an increasingly important role in the detection and
localization of clinically significant PCa. Despite the demonstrated value of prostate MRI, there are two major
challenges in clinical implementation of prostate MRI as a first-line screening tool at a population level: (1) high
cost of the scanner and the exam, which decreases accessibility, and (2) lack of robustness of the MRI exam.
To overcome these limitations we propose establishing a low-field, robust, widely accessible, and thus low-
cost high-performance MRI system for PCa screening. Major challenges for imaging at lower field strength
is the lower signal to noise (SNR) and thus longer acquisition times compared to 1.5 and 3.0 T. In this
proposal we aim to address these efficiency and scan time challenges at low field. Our team of clinical
and imaging scientists will bring to bear novel acquisition and reconstruction techniques to restore SNR,
specifically random matrix theory (RMT- a technique our center has recently introduced), and deep-learning-
based image reconstruction (an area our group has helped to pioneer). We will evaluate these techniques in
healthy volunteers and patients with PCa. Subsequently, we will perform head-to-head comparison of low-field
bi-parametric exam to routine clinical 1.5 T or 3.0 T MRI exams in 30 patients with known or suspected PCa.
项目摘要/摘要
前列腺癌(Pca)是最常见的恶性肿瘤,是癌症相关死亡的第二大原因。
在美国的男性中。尽管PCA的发病率很高,对人类和经济造成了巨大的影响,
对于具有临床意义的前列腺癌,目前尚无良好的筛查试验。前列腺特异性的常用血液检测方法
抗原(PSA)价格低廉,但对有临床意义的PCa缺乏特异性。在过去的十年里,多
参数前列腺MRI已被证明在检测和诊断前列腺癌方面发挥着越来越重要的作用。
临床上有意义的前列腺癌的定位。尽管前列腺核磁共振的价值得到了证实,但有两个主要原因
作为人群一级筛查工具的前列腺癌MRI临床应用面临的挑战:(1)高
扫描仪和检查的成本,这降低了可访问性,以及(2)MRI检查缺乏稳健性。
为了克服这些限制,我们建议建立一个低场、健壮、可广泛访问的,从而
性价比高的高性能核磁共振系统用于前列腺癌筛查。低场强成像面临的主要挑战
与1.5和3.0 T相比,信噪比(SNR)更低,因此采集时间更长。
我们的目标是在低场下解决这些效率和扫描时间的挑战。我们的临床团队
成像科学家将采用新的采集和重建技术来恢复SNR,
特别是随机矩阵理论(RMT-我们中心最近引入的一种技术),以及深度学习-
基于图像重建(我们团队帮助开创的一个领域)。我们将在以下项目中评估这些技术
健康志愿者和前列腺癌患者。随后,我们将进行低场的面对面比较
对30例已知或疑似前列腺癌患者进行常规1.5T或3.0T磁共振检查的双参数检查。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hersh Chandarana其他文献
Hersh Chandarana的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hersh Chandarana', 18)}}的其他基金
Advanced Diffusion Imaging for Management of Renal Cancer: Oncologic Control and Renal Functional Reserve - Resubmission - 1
用于肾癌治疗的先进扩散成像:肿瘤控制和肾功能储备 - 重新提交 - 1
- 批准号:
10380147 - 财政年份:2020
- 资助金额:
$ 19.41万 - 项目类别:
Advanced Diffusion Imaging for Management of Renal Cancer: Oncologic Control and Renal Functional Reserve - Resubmission - 1
用于肾癌治疗的先进扩散成像:肿瘤控制和肾功能储备 - 重新提交 - 1
- 批准号:
10212354 - 财政年份:2020
- 资助金额:
$ 19.41万 - 项目类别:
Advanced Diffusion Imaging for Management of Renal Cancer: Oncologic Control and Renal Functional Reserve - Resubmission - 1
用于肾癌治疗的先进扩散成像:肿瘤控制和肾功能储备 - 重新提交 - 1
- 批准号:
10625960 - 财政年份:2020
- 资助金额:
$ 19.41万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.41万 - 项目类别:
Research Grant